Pharmacology: Case Western Reserve University

CASE.EDU: HOME | DIRECTORIES | SEARCH

Keri Publications

1:	Landis, M.D., Seachrist, D.D., Abdul-Karim, F., and Keri, R.A. 2006. Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors. Oncogene, 25:3325-3334.
	Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors. Oncogene. 2006 Jan 23.

2:	Milliken EL, Zhang X, Flask C, Duerk JL, MacDonald PN, Keri RA.
	EB1089, a vitamin D receptor agonist, reduces proliferation and decreases tumor growth rate in a mouse model of hormone-induced mammary cancer. Cancer Lett. 2005 Nov 18;229(2):205-15.

3:	Landis MD, Seachrist DD, Montanez-Wiscovich ME, Danielpour D, Keri RA.
	Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice. Oncogene. 2005 Aug 4;24(33):5173-90.

4:	Knostman KA, Cho JY, Ryu KY, Lin X, McCubrey JA, Hla T, Liu CH, Di Carlo E, Keri R, Zhang M, Hwang DY, Kisseberth WC, Capen CC, Jhiang SM.
	Signaling through 3',5'-cyclic adenosine monophosphate and phosphoinositide-3 kinase induces sodium/iodide symporter expression in breast cancer. J Clin Endocrinol Metab. 2004 Oct;89(10):5196-203.

5:	Mann RJ, Keri RA, Nilson JH.
	Consequences of elevated luteinizing hormone on diverse physiological systems: use of the LHbetaCTP transgenic mouse as a model of ovarian hyperstimulation-induced pathophysiology. Recent Prog Horm Res. 2003;58:343-75. Review.

6:	Kero JT, Savontaus E, Mikola M, Pesonen U, Koulu M, Keri RA, Nilson JH, Poutanen M, Huhtaniemi IT.
	Obesity in transgenic female mice with constitutively elevated luteinizing hormone secretion. Am J Physiol Endocrinol Metab. 2003 Oct;285(4):E812-8. Epub 2003 May 28.

7:	Mikola M, Kero J, Nilson JH, Keri RA, Poutanen M, Huhtaniemi I.
	High levels of luteinizing hormone analog stimulate gonadal and adrenal tumorigenesis in mice transgenic for the mouse inhibin-alpha-subunit promoter/Simian virus 40 T-antigen fusion gene. Oncogene. 2003 May 22;22(21):3269-78.

8:	Milliken EL, Ameduri RK, Landis MD, Behrooz A, Abdul-Karim FW, Keri RA.
	Ovarian hyperstimulation by LH leads to mammary gland hyperplasia and cancer predisposition in transgenic mice. Endocrinology. 2002 Sep;143(9):3671-80.

9:	Owens GE, Keri RA, Nilson JH.
	Ovulatory surges of human CG prevent hormone-induced granulosa cell tumor formation leading to the identification of tumor-associated changes in the transcriptome. Mol Endocrinol. 2002 Jun;16(6):1230-42.

10:	Hodges CA, Ilagan A, Jennings D, Keri R, Nilson J, Hunt PA.
	Experimental evidence that changes in oocyte growth influence meiotic chromosome segregation. Hum Reprod. 2002 May;17(5):1171-80.

11:	Quirk CC, Lozada KL, Keri RA, Nilson JH.
	A single Pitx1 binding site is essential for activity of the LHbeta promoter in transgenic mice. Mol Endocrinol. 2001 May;15(5):734-46.

12:	Nilson JH, Abbud RA, Keri RA, Quirk CC.
	Chronic hypersecretion of luteinizing hormone in transgenic mice disrupts both ovarian and pituitary function, with some effects modified by the genetic background. Recent Prog Horm Res. 2000;55:69-89; discussion 89-91. Review.

13:	Keri RA, Bachmann DJ, Behrooz A, Herr BD, Ameduri RK, Quirk CC, Nilson JH.
	An NF-Y binding site is important for basal, but not gonadotropin-releasing hormone-stimulated, expression of the luteinizing hormone beta subunit gene. J Biol Chem. 2000 Apr 28;275(17):13082-8.

14:	Kero J, Poutanen M, Zhang FP, Rahman N, McNicol AM, Nilson JH, Keri RA, Huhtaniemi IT.
	Elevated luteinizing hormone induces expression of its receptor and promotes steroidogenesis in the adrenal cortex. J Clin Invest. 2000 Mar;105(5):633-41.

15:	Keri RA, Lozada KL, Abdul-Karim FW, Nadeau JH, Nilson JH.
	Luteinizing hormone induction of ovarian tumors: oligogenic differences between mouse strains dictates tumor disposition. Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):383-7.

16:	Mann RJ, Keri RA, Nilson JH.
	Transgenic mice with chronically elevated luteinizing hormone are infertile due to anovulation, defects in uterine receptivity, and midgestation pregnancy failure. Endocrinology. 1999 Jun;140(6):2592-601.

17:	Farmerie TA, Abbud RA, Budworth PR, Clay CM, Keri RA, McDowell KJ, Wolfe MW, Nilson JH.
	Characterization of the equine glycoprotein hormone alpha-subunit gene reveals divergence in the mechanism of pituitary and placental expression. Biol Reprod. 1997 Nov;57(5):1104-14.

18:	Keri RA, Nilson JH.
	A steroidogenic factor-1 binding site is required for activity of the luteinizing hormone beta subunit promoter in gonadotropes of transgenic mice. J Biol Chem. 1996 May 3;271(18):10782-5.

19:	Camper SA, Saunders TL, Kendall SK, Keri RA, Seasholtz AF, Gordon DF, Birkmeier TS, Keegan CE, Karolyi IJ, Roller ML, et al.
	Implementing transgenic and embryonic stem cell technology to study gene expression, cell-cell interactions and gene function. Biol Reprod. 1995 Feb;52(2):246-57. Review.

20:	Keri RA, Wolfe MW, Saunders TL, Anderson I, Kendall SK, Wagner T, Yeung J, Gorski J, Nett TM, Camper SA, et al.
	The proximal promoter of the bovine luteinizing hormone beta-subunit gene confers gonadotrope-specific expression and regulation by gonadotropin-releasing hormone, testosterone, and 17 beta-estradiol in transgenic mice. Mol Endocrinol. 1994 Dec;8(12):1807-16.

21:	Clay CM, Keri RA, Finicle AB, Heckert LL, Hamernik DL, Marschke KM, Wilson EM, French FS, Nilson JH.
	Transcriptional repression of the glycoprotein hormone alpha subunit gene by androgen may involve direct binding of androgen receptor to the proximal promoter. J Biol Chem. 1993 Jun 25;268(18):13556-64.

22:	Hamernik DL, Keri RA, Clay CM, Clay JN, Sherman GB, Sawyer HR Jr, Nett TM, Nilson JH.
	Gonadotrope- and thyrotrope-specific expression of the human and bovine glycoprotein hormone alpha-subunit genes is regulated by distinct cis-acting elements. Mol Endocrinol. 1992 Oct;6(10):1745-55.

23:	Kendall SK, Saunders TL, Jin L, Lloyd RV, Glode LM, Nett TM, Keri RA, Nilson JH, Camper SA.
	Targeted ablation of pituitary gonadotropes in transgenic mice. Mol Endocrinol. 1991 Dec;5(12):2025-36.

24:	Keri RA, Andersen B, Kennedy GC, Hamernik DL, Clay CM, Brace AD, Nett TM, Notides AC, Nilson JH.
	Estradiol inhibits transcription of the human glycoprotein hormone alpha-subunit gene despite the absence of a high affinity binding site for estrogen receptor. Mol Endocrinol. 1991 May;5(5):725-33.

25:	Nilson JH, Bokar JA, Clay CM, Farmerie TA, Fenstermaker RA, Hamernik DL, Keri RA.
	Different combinations of regulatory elements may explain why placenta-specific expression of the glycoprotein hormone alpha-subunit gene occurs only in primates and horses. Biol Reprod. 1991 Feb;44(2):231-7. Review.

26:	Bokar JA, Keri RA, Farmerie TA, Fenstermaker RA, Andersen B, Hamernik DL, Yun J, Wagner T, Nilson JH.
	Expression of the glycoprotein hormone alpha-subunit gene in the placenta requires a functional cyclic AMP response element, whereas a different cis-acting element mediates pituitary-specific expression. Mol Cell Biol. 1989 Nov;9(11):5113-22.

27:	Nilson JH, Bokar JA, Andersen B, Bohinski R, Kennedy G, Keri RA, Farmerie TA, Fenstermaker RA.
	CRE-binding proteins interact cooperatively to enhance placental-specific expression of the glycoprotein hormone alpha-subunit gene. Ann N Y Acad Sci. 1989;564:77-85.
28:	Mosley, J.D. and Keri, R.A. 2006.
	Splice variants of mIAP1 have an enhanced ability to inhibit apoptosis. Biochem. Biophys. Res. Comm. 348:1174-1183.
29:	Casadesus, G., Milliken, E.L., Webber, K.M., Bowen, R.L., Lei, Z.M., Rao, C.V., Atwood, C.S., Perry, G. Keri, R.A., and Smith, M.A. 2006.
	Declines in cognitive performance are associated with increased luteinizing hormone levels in mice. Mol. Cell. Endocrinol. 269:107-111.
30:	Mosley, J.D., Poirier, J.T., Seachrist, D.D., Landis, M.D., and Keri, R.A. 2007.
	Rapamycin Inhibits Multiple Stages of c-Neu/ErbB2-induced Tumor Progression in a Transgenic Mouse Model of HER2 Positive Breast Cancer. Mol. Cancer Ther. 6:2188-2197.
31:	Keri, R.A., Ho, S.-M., Hunt, P.A., Knudsen, K.E., Soto, A.M., and Prins, G. 2007.
	An Evaluation of Evidence for the Carcinogenic Activity of Bisphenol A. Reprod. Toxicol., 24:240-252.
32:	Sutton, A. and Keri, R.A. 2007.
	The pleiotropic effects of excessive LH secretion in transgenic mice. Semin. Reprod. Med., 25:360-367.
33:	vom Saal, F.S., Akingbemi, B.T., Belcher, S.M., Birnbaum, L.S., Crain, D.A., Eriksen, M., Guillette, L.J., Hauser, R., Heindel, J.J., Ho, S-M., Iguchi, T., Jobling, S., Kanno, J., Keri, R.A., Knudsen, K.E., LeBlanc, G.A., Marcus, M., McLachlan, J.A., Myers, J.P., Nadal, A., Newbold, R.R., Olea, N., Prins, G., Richter, C.A., Rubin, B.S., Sonnenschein, C., Soto, A.M., Talsness, C.E., Vandenberg, L.N., Walsen-Kuntz, D.R., Watson, C.S., Welshons, W.V., Wetherill, Y., Zoeller, R.T. 2007.
	Chapel Hill bisphenol A expert panel consensus statement: Integration of mechanisms, effects in animals and potential to impact human health at current levels of exposure. Reprod. Toxicol.,24:131-138.
34:	Milliken, E.L., Lozada, K.L., Johnson, E., Landis, M.D., Seachrist, D.D., Whitten, I., Sutton, A.L.M., Abdul-Karim, F.W., and Keri, R.A. 2007.
	Ovarian hyperstimulation induces centrosome amplification and aneuploid mammary tumors independently of alterations in p53 in a transgenic mouse model of breast cancer. Oncogene, in press.